Skip to content
Open access

Exploring metabolic candidates and inflammatory mediation in Parkinson’s disease: a pilot integrative metabolomics and Mendelian randomization study

Sep 2026 · PeerJ · Vol 14, pp. e21670 · 0 citations · 37 references
Medicine

TL;DR

This exploratory study integrates pilot-scale metabolomics with genetic analyses to identify candidate metabolic signals and inflammatory pathways linked to PD and indicated that SULT1A1 may partially mediate the association between 3-phenylpropionylglycine and PD.

Abstract

Background Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by multifaceted molecular dysregulation. Integrating genetic approaches with metabolomics may help to systematically investigate potential links between metabolites, inflammatory proteins, and PD risk. Methods In this pilot discovery phase, untargeted Liquid Chromatography-Mass Spectrometry (LC-MS) was conducted in a small cohort (15 PD patients and 10 healthy controls). Differentially expressed metabolites (DEMs) were identified using variable importance in projection (VIP) > 1, |log2FC| ≥ 1, and false discovery rate (FDR)-adjusted q-values < 0.05 (Benjamini–Hochberg method), representing the metabolites remaining significant after multiple-testing correction applied directly at the metabolite discovery stage. Prioritized metabolites were selected by Random Forest, Least absolute shrinkage and selection operator (LASSO) regression, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Two-sample Mendelian randomization (MR) was performed using PD Genome-Wide Association Study (GWAS) data from FinnGen R12 (European ancestry: 5,861 cases, 494,487 controls) to evaluate putative causal associations, with FDR correction applied separately within the metabolite and inflammatory protein exposure sets. Mediation MR was used to explore potential mediating roles of 91 circulating inflammatory proteins. Results A total of 3,537 metabolites were identified, of which 570 were classified as DEMs, representing the features remaining significant after multiple-testing correction. Integration of Random Forest and LASSO identified 3-phenylpropionylglycine as a key candidate metabolite. KEGG analysis highlighted caffeine metabolism as the top enriched pathway. After FDR correction, MR analyses suggested inverse associations between genetically predicted levels of 3-phenylpropionylglycine (PFDR = 0.0077, OR = 0.82) and 7-methylxanthine (PFDR = 0.0349, OR = 0.83) and PD risk. Mediation analysis further indicated that SULT1A1 may partially mediate the association between 3-phenylpropionylglycine and PD. Conclusion This exploratory study integrates pilot-scale metabolomics with genetic analyses to identify candidate metabolic signals and inflammatory pathways linked to PD. However, given the small metabolomics sample size, cross-cohort data integration, and potential biological mismatch between plasma-derived metabolites and genetically predicted metabolite levels, these findings should be considered hypothesis-generating and interpreted with caution.

Read PDF

Similar papers

Oct 2026

Prioritizing MMP8 as an exploratory therapeutic candidate in Parkinson's disease through proteome-wide Mendelian randomization and computational multi-omics integration.

The 32 proteins with nominal MR associations represent candidates for follow-up investigation and should be interpreted as exploratory because a verified proteome-wide FDR correction could not be established.

Hong-Yuan Zhang, Jing Zou, Yan-Hong Zhao et al. · 0 citations
Open access Nov 2026

Identification and validation of biomarkers associated with mitochondrial dynamics dysfunction in Parkinson’s disease based on GEO datasets

Background Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder, is characterized by an unclear etiology and a lack of specific early diagnostic biomarkers. This study investigated novel biomarkers associated with mitochondrial dynamics (MD) dysfunction in PD. Methods Transcriptomic data from...

D. Gong, Guan-Yu Li, Ming-Hua Li et al. · 0 citations
Open access Nov 2026

Multi-Omics Mendelian Randomization Identifies DDX17 as a Potential Mediator Linking Gut Microbiota-Immune-Metabolism Axis to Alzheimer’s Disease

Introduction The gut microbiota-immune-metabolism axis has been implicated in Alzheimer’s disease (AD) pathogenesis; however, the key host molecular targets linking peripheral dysregulation to central neurodegeneration remain elusive. Methods In this study, we systematically integrated large-scale GWAS data covering 1,...

Zhen Xiao, Ya-Man Qin, Ming-You Dong et al. · 0 citations
Open access Sep 2026

Multi-Omics Integration of Transcriptomics and Metabolomics with Machine Learning Uncovers Novel Risk Factors for Alzheimer’s disease

Multi-omics integration identified candidate biomarkers reflecting inflammatory signaling, mitochondrial dysfunction, and lipid metabolism reflecting inflammatory signaling, mitochondrial dysfunction, and lipid metabolism as well as influential genes and metabolites associated with cognition in Alzheimer's disease.

Jerome J. Choi, C. Engelman, Tian-Yuan Lu · 0 citations
Open access Nov 2026

Serum Metabolomic Profiling and Clinical Phenotypes in Parkinson's Disease: A Case-Control Study.

Parkinson's disease (PD) is characterized by heterogeneous motor and non-motor symptoms, but serum metabolic features related to this variability remain unclear. To address this, this small-scale study investigated serum metabolic alterations in patients with PD and explored their relationships with clinical features....

Jia-Le Li, Ru-Lin Geng, Jie-Li Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.